Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 28:14:1355715.
doi: 10.3389/fonc.2024.1355715. eCollection 2024.

Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing

Affiliations

Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing

Iulian O Ban et al. Front Oncol. .

Abstract

Introduction: Accurate identification and characterization of Large Genomic Rearrangements (LGR), especially duplications, are crucial for precise diagnosis and risk assessment. In this report, we characterized an intragenic duplication breakpoint of PALB2 to determine its pathogenicity significance.

Methods: A 52-year-old female with triple-negative breast cancer was diagnosed with a novel PALB2 LGR. An efficient and accurate methodology was applied, combining long-read sequencing and transcript analysis for the rapid characterization of the duplication.

Results: Duplication of exons 5 and 6 of PALB2 was validated by transcript analysis. Long-read sequencing enabled the localization of breakpoints within Alu elements, providing insights into the mechanism of duplication via non-allelic homologous recombination.

Conclusion: Using our combined methodology, we reclassified the PALB2 duplication as a pathogenic variant. This reclassification suggests a possible causative link between this specific genetic alteration and the aggressive phenotype of the patient.

Keywords: LGR; PALB2; breast cancer; long-read sequencing; molecular alteration.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Comprehensive Analysis and Characterization of Tandem Duplications in PALB2. (A) MLPA assay of PALB2. Each dot represents the amplification ratio of a specific probe pair, reflecting the relative amount of the targeted DNA segment compared to three reference samples. Error bars indicate the standard deviation of the measured ratio. The ratio is calculated for each probe and indicates whether there is a deletion (ratio <1), duplication (ratio >1), or no change (ratio ≈1). (B) Sanger sequencing electropherogram of the proband’s cDNA, with black arrows marking the primer positions. The orange shallow points the targeted region. F, forward; R, reverse.
Figure 2
Figure 2
Identification and characterization of the Tandem Duplication Breakpoint in PALB2. (A) IGV visualization of Nanopore Long-Read Sequencing. Purple rectangle depict the genomic length of the insertion. The colored bars, in shades of red and blue, represent sequencing reads that span PALB2 exons 4 to 7. (B) Density estimation plot of insertion length detected by long read sequencing. The discontinuous red line shows the exact insertion length determined by Sanger sequencing. (C) Sanger sequencing electropherogram of the genomic breakpoint region. Black arrows mark the primer positions. The orange shallow points the targeted region. F, forward; R, reverse; I, intron; E, exon.

References

    1. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. (2012) 12:68–78. doi: 10.1038/nrc3181 - DOI - PMC - PubMed
    1. Loveday C, Garrett A, Law P, Hanks S, Poyastro-Pearson E, Adlard JW, et al. . Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes. Ann Oncol. (2022) 33:1318–27. doi: 10.1016/j.annonc.2022.09.152 - DOI - PubMed
    1. Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer. (2020) 126:549–58. doi: 10.1002/cncr.32572 - DOI - PMC - PubMed
    1. Hanenberg H, Andreassen PR. PALB2 (partner and localizer of BRCA2). Atlas Genet Cytogenet Oncol Haematol. (2018) 22:484–90. doi: 10.4267/2042/69016 - DOI - PMC - PubMed
    1. Foo TK, Xia B. BRCA1-dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer. Cancer Res. (2022) 82:3191–7. doi: 10.1158/0008-5472.CAN-22-1535 - DOI - PMC - PubMed

LinkOut - more resources